Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) is considered one of the best stocks to buy under $20.
On September 19, Syndax Pharmaceuticals announced a significant milestone. The National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia (AML) to include Revuforj (revumenib).
Revuforj received a Category 2A recommendation for the treatment of relapsed AML, marking an important step forward for the therapy and the company.
https://ca.finance.yahoo.com/news/syndax-revumenib-added-nccn-aml-205447064.html